Are Mylan Results Enough for Investors?
Mylan stock pulled back on Friday after it reported mixed fourth-quarter financial results late Thursday.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 70
Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development
Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many cases it is far cheaper to just partner up with these smaller and more…
Teladoc’s Model Supports Strong Growth and Anti-Coronavirus Trading
Teladoc Health is a company that may actually be winning because of the coronavirus outbreak, even if it likely hasn't seen much of a boost from the virus on its business yet.
Big Pharma Scares Off Short Sellers
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Major Biotechs Have Short Sellers Confused
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
How Novavax Is Differentiating Itself From Other Coronavirus Stocks
Novavax shares made a big step forward on Wednesday after the firm provided an update on its treatment for COVID-19.
Hope for Gilead’s Remdesivir to Beat the Coronavirus
Gilead Sciences stock surged while the broader market was battered on reports that a senior official from the World Health Organization said that Gilead's remdesivir may currently be the best bet on defeating the…
Natural Hedges for Coronavirus Fear Beating Up the Broad Markets
The broad markets are getting crushed on Monday on renewed fears of the spread of the coronavirus (Covid-19). But a handful of stocks were acting as a natural hedge to the virus news.
This FDA Approval of Karyopharm’s Lymphoma Treatment Could Be Huge
Karyopharm Therapeutics shares made a handy gain on Wednesday after the firm secured a key FDA nod for its relapsed or refractory diffuse large B-cell lymphoma treatment.
Artificial Intelligence and Machine Learning in the Operating Room
Researchers have conducted a trial of a device that alerts anesthesiologists to a possible low-blood-pressure event for patients in surgery. The alerts come 15 minutes before the event could occur.
Why Teva’s Grand Turnaround Could Just Be Getting Started
See why Argus believes that Teva Pharmaceutical has made progress concerning its challenges, which are already baked into the stock price.
Why Biogen Fits Well With Warren Buffett and Berkshire Hathaway, Even With Biotech Risks
Investors are not used to hearing is the word "biotech" used in the same sentence as anything to do with Warren Buffett and Berkshire Hathaway. Yet the portfolio managers have purchased shares of Biogen.
How Delayed Drug Approval Is Punishing Bio-Path Stock
What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of shareholder value? That's what happened to Bio-Path.
Why This Analyst Sees New Contraceptive FDA Approval Doubling Agile Therapeutics Stock
Agile Therapeutics shares took a dip on Tuesday after the company announced a key FDA approval for its new weekly contraceptive patch. Yet, one analyst sees great long-term potential, targeting the stock to more…
3 SunTrust Buy-Rated Biotech Stocks Have Massive Upside Potential
These three biotech stocks have gigantic upside and a fair amount of risk as well. While they are not suited for conservative accounts, the companies all have had very positive data and their shares…